The effect of single-dose losartan on the basic effects of cognitive-behaviour therapy for panic disorder - a randomized double blind placebo-controlled trial - Cognitive-behaviour therapy and losartan

niversity of Oxford0 个研究点开始时间: 2015年11月4日最近更新: 2016年5月2日

适应症

试验速览

暂无简介。

•*Participant is willing and able to give informed consent for participation in the study and to comply with all study requirements
•*Male or Female, aged 18 years or above
•*Diagnosed with DSM-IV panic disorder
•*At least moderate avoidance of agoraphobic situations (”yes” response to at least 3 situations listed under (2) Avoidance – Do you avoid or feel very uncomfortable in …” in the Structured Panic Assessment Interview (Clark, 1989)
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 35
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 5

•*Female participant who is pregnant or breast-feeding
•*CNS-active medication during the last 6 weeks
•*Current blood pressure or other heart medication (especially aliskiren or beta blockers)
•*Intravascular fluid depletion
•*Impaired liver or kidney function
•*Lifetime history of epilepsy or other neurological disease, systemic infection, or clinically significant hepatic, cardiac, obstructive respiratory, renal, cerebrovascular, metabolic, endocrine or pulmonary disease or disorder which, in the opinion of the investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant’s ability to participate in the study.
•*Lifetime history of psychosis, bipolar disorder, alcohol, medication or drug abuse or dependence; current primary depressive disorder
•*Insufficient English skills
•*Participated in another study involving certain medication during the last 6 weeks
•*Exposure-based psychological treatment for panic disorder and agoraphobia during the last 3 months
•*Patient not able to refrain from benzodiazepines 48hrs before treatment and testing sessions
•Participants with MRI contraindications (e.g. pacemaker, metal implant, left-handedness) will be included in the study but will not undergo the MRI scan study component.

发起方